Revvity, Inc. (NYSE: RVTY) has reported its financial results for the third quarter of 2025, indicating a revenue of $699 million, representing a 2% reported growth and a 1% organic growth compared to the same period last year.
The company's GAAP earnings per share (EPS) for the quarter stood at $0.40, down from $0.77 in the corresponding period a year ago. Meanwhile, adjusted EPS from continuing operations was $1.18, a decrease from $1.28 in the same period last year.
Revvity's GAAP operating income from continuing operations for the quarter was $82 million, a decline from $98 million in the same period a year ago. The GAAP operating profit margin from continuing operations also decreased to 11.7% of revenue, down from 14.3% in the same period last year.
Adjusted operating income for the quarter was $182 million, down from $193 million for the same period a year ago, with the adjusted operating profit margin reducing to 26.1% of revenue from 28.3% in the same period last year.
The company's board of directors has authorized a new two-year $1 billion share repurchase program, replacing the prior program announced in October 2024.
In terms of segment performance, the life sciences segment reported revenue of $343 million, up 1% from the same period a year ago, while the diagnostics segment recorded revenue of $356 million, reflecting a 3% increase from the corresponding period last year.
Looking ahead, Revvity has updated its full-year revenue guidance to $2.83-$2.88 billion and is reaffirming its organic growth guidance of 2% to 4%. The company has also raised its adjusted EPS guidance to a range of $4.90 to $5.00 for the full year 2025.
The market has reacted to these announcements by moving the company's shares 1.35% to a price of $98.89. If you want to know more, read the company's complete 8-K report here.
